Illumina Inc.

Illumina is engaged in sequencing- and array-based solutions for genetic and genomic analysis. The company provides whole-genome sequencing, genotyping, noninvasive prenatal testing (NIPT), and product support services. Using the company's services, customers can perform whole-genome sequencing projects and microarray projects (including large-scale genotyping studies and whole-genome association studies). The company provides NIPT services through its partner laboratories that direct samples to the company on a test send-out basis in its Clinical Laboratory Improvements Amendments-certified, College of Pathologists-accredited laboratory. The company also provides support services to customers who have purchased its products.
  • TickerILMN
  • ISINUS4523271090
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States
ILMN ILLUMINA INC. (Health Care)

ILLUMINA reduces its risk exposure and slightly improves to Neutral

The independent financial analyst theScreener just allocated a lower risk rating to ILLUMINA (US), active in the Biotechnology industry. As regards its fundamental valuation, the title still shows 2 out of 4 possible stars. Its market behaviour, however, has slightly improved and can be qualified as moderately risky. theScreener considers that these elements merit an overall rating upgrade to Neutral. As of the analysis date July 20, 2021, the closing price was USD 487.25 and its expected value was estimated at USD 450.67.

ILMN ILLUMINA INC. (Health Care)

Illumina Inc: 2 directors

Two Directors at Illumina Inc sold/sold after exercising options 2,000 shares at between 447.589USD and 450.000USD. The significance rating of the trade was 58/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is r...

 PRESS RELEASE
ILMN ILLUMINA INC. (Health Care)

Illumina Supports Nationwide Program across Belgium to Assess Whole Ge...

SAN DIEGO--(BUSINESS WIRE)-- Today, Illumina, Inc. (NASDAQ:ILMN) announced an agreement with the Belgian Genetic Centers to evaluate whole-genome sequencing (WGS) for the diagnosis of patients with intellectual disabilities (ID) and/or developmental disorders (DD) in routine care. The study, run by the Belgian Resolve Rare Diseases group (BeSolveRD), will also assess the health economic impact of WGS versus current standards of care. BeSolveRD will recruit 800 pediatric patients (neonates, children or adolescents) with ID/DD, plus their parents, from all eight Belgian Genetic Centers. Half of...

 PRESS RELEASE
ILMN ILLUMINA INC. (Health Care)

Illumina and Next Generation Genomic Partner to Launch VeriSeq™ NIPT S...

MELBOURNE, Australia--(BUSINESS WIRE)-- Illumina, Inc., the global leader in DNA sequencing and array-based technologies and Next Generation Genomic Co., Ltd. (NGG Thailand), the Association of Southeast Asian Nations (ASEAN) leaders in laboratory services and reproductive science, today announced the launch of VeriSeq™ NIPT Solution v2 in Thailand, a CE-IVD, next-generation sequencing (NGS)-based approach to noninvasive prenatal testing (NIPT). This press release features multimedia. View the full release here: Illumina's VeriSeq NIPT Solution v2 (Photo: Business Wire) The automated in-lab IV...

 PRESS RELEASE
ILMN ILLUMINA INC. (Health Care)

Illumina To Webcast Upcoming Investor Conference

SAN DIEGO--(BUSINESS WIRE)-- Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference: Goldman Sachs 42nd Annual Global Healthcare Conference on June 10, 2021 Fireside Chat at 7:30 am Pacific Time / 10:30 am Eastern Time The live webcast can be accessed under the Investor Info section of the "company" tab at . A replay will be posted on Illumina’s website after the event and will be available for at least 30 days following. About Illumina Illumina is improving human health by unlocking the power of the genome. Our focus on in...

ILMN ILLUMINA INC. (Health Care)

Illumina Inc: 2 directors

Two Directors at Illumina Inc sold/sold after exercising options 2,000 shares at between 447.589USD and 450.000USD. The significance rating of the trade was 58/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is r...

 PRESS RELEASE
ILMN ILLUMINA INC. (Health Care)

Illumina Supports Nationwide Program across Belgium to Assess Whole Ge...

SAN DIEGO--(BUSINESS WIRE)-- Today, Illumina, Inc. (NASDAQ:ILMN) announced an agreement with the Belgian Genetic Centers to evaluate whole-genome sequencing (WGS) for the diagnosis of patients with intellectual disabilities (ID) and/or developmental disorders (DD) in routine care. The study, run by the Belgian Resolve Rare Diseases group (BeSolveRD), will also assess the health economic impact of WGS versus current standards of care. BeSolveRD will recruit 800 pediatric patients (neonates, children or adolescents) with ID/DD, plus their parents, from all eight Belgian Genetic Centers. Half of...

 PRESS RELEASE
ILMN ILLUMINA INC. (Health Care)

Illumina and Next Generation Genomic Partner to Launch VeriSeq™ NIPT S...

MELBOURNE, Australia--(BUSINESS WIRE)-- Illumina, Inc., the global leader in DNA sequencing and array-based technologies and Next Generation Genomic Co., Ltd. (NGG Thailand), the Association of Southeast Asian Nations (ASEAN) leaders in laboratory services and reproductive science, today announced the launch of VeriSeq™ NIPT Solution v2 in Thailand, a CE-IVD, next-generation sequencing (NGS)-based approach to noninvasive prenatal testing (NIPT). This press release features multimedia. View the full release here: Illumina's VeriSeq NIPT Solution v2 (Photo: Business Wire) The automated in-lab IV...

 PRESS RELEASE
ILMN ILLUMINA INC. (Health Care)

Illumina To Webcast Upcoming Investor Conference

SAN DIEGO--(BUSINESS WIRE)-- Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference: Goldman Sachs 42nd Annual Global Healthcare Conference on June 10, 2021 Fireside Chat at 7:30 am Pacific Time / 10:30 am Eastern Time The live webcast can be accessed under the Investor Info section of the "company" tab at . A replay will be posted on Illumina’s website after the event and will be available for at least 30 days following. About Illumina Illumina is improving human health by unlocking the power of the genome. Our focus on in...

 PRESS RELEASE
ILMN ILLUMINA INC. (Health Care)

Illumina Appoints Susan Tousi as Chief Commercial Officer and Dr. Alex...

SAN DIEGO--(BUSINESS WIRE)-- Illumina, Inc. (NASDAQ: ILMN) today announced that it is appointing Susan Tousi as Chief Commercial Officer (CCO), and Dr. Alex Aravanis as Chief Technology Officer (CTO), Head of Research and Product Development. “We’re fortunate to have Susan and Alex, two of the strongest leaders in the genomics industry, take on these large, important roles,” said Francis deSouza, Chief Executive Officer of Illumina. “Susan and Alex are talented and passionate executives with successful track records of creating a compelling vision, building great teams, delivering exceptional...

Valens Research
  • Valens Research
ILMN ILLUMINA INC. (Health Care)

ILMN - Embedded Expectations Analysis - 2021 01 05

Illumina, Inc. (ILMN:USA) currently trades above corporate averages relative to UAFRS-based (Uniform) earnings, with a 46.5x Uniform P/E. At these levels, the market is pricing in bullish expectations for the firm, but management may be concerned about declining margins, the GRAIL acquisition, and NGS technology Specifically, management may lack confidence in their ability to mitigate margin declines and sustain noninvasive prenatal testing (NIPT) business growth. In addition, they may have concerns about the sustainability of Novaseq and Nextseq demand and the recovery of consumables demand....

Valens Research
  • Valens Research
ILMN ILLUMINA INC. (Health Care)

ILMN - Embedded Expectations Analysis - 2020 11 13

Illumina, Inc. (ILMN:USA) currently trades above corporate averages relative to UAFRS-based (Uniform) earnings, with a 38.1x Uniform P/E. Even at these levels, the market is pricing in expectations for profitability to remain near recent lows, and management may be concerned about academic market uncertainties, TrueSight Software Suite's potential, and sequencing platform development Specifically, management may lack confidence in their ability to secure more sequencing opportunities and sustain innovation momentum across the entire sequencing workflow. Management may also be exaggerating inc...

Michael Waterhouse
  • Michael Waterhouse
ILMN ILLUMINA INC. (Health Care)

Morningstar | Dropping Coverage of Illumina

We are dropping coverage of Illumina. We provide broad coverage of more than 1,500 companies globally and periodically adjust our coverage according to investor interest and staffing. We expect to reinitiate coverage of Illumina in the next few months.

Michael Waterhouse
  • Michael Waterhouse
ILMN ILLUMINA INC. (Health Care)

Dropping Coverage of Illumina

We are dropping coverage of Illumina. We provide broad coverage of more than 1,500 companies globally and periodically adjust our coverage according to investor interest and staffing. We expect to reinitiate coverage of Illumina in the next few months. ...

Michael Waterhouse
  • Michael Waterhouse
ILMN ILLUMINA INC. (Health Care)

Morningstar | Illumina Under Review

We are placing Illumina under review as we transfer coverage to a new analyst. We expect to publish a new fair value estimate in the second quarter.

ILMN ILLUMINA INC. (Health Care)

Moody's announces completion of a periodic review of ratings of Illumi...

Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Illumina, Inc.. Global Credit Research- 14 Apr 2021. New York, April 14, 2021-- Moody's Investors Service has completed a periodic review of the ratings of Illumina, Inc. and other ratings that are associated with the same analytical unit.

ILMN ILLUMINA INC. (Health Care)

Illumina, Inc.: New issuer in gene sequencing and cancer screening

Illumina's credit profile is supported by its leading position in gene sequencing and strong cash flow which helps offset higher leverage related to the $8 billion acquisition of GRAIL.

ILMN ILLUMINA INC. (Health Care)

Moody's assigns Baa3 rating to Illumina's notes offering

Rating Action: Moody's assigns Baa3 rating to Illumina's notes offering. Global Credit Research- 16 Mar 2021. New York, March 16, 2021-- Moody's Investors Service, assigned a Baa3 rating to the proposed offering of $1 billion of senior unsecured notes of Illumina, Inc.

ILMN ILLUMINA INC. (Health Care)

Moody's assigns a first-time Baa3 issuer rating to Illumina; outlook s...

Rating Action: Moody's assigns a first-time Baa3 issuer rating to Illumina; outlook stable. Global Credit Research- 08 Mar 2021. NOTE: Due to an internal administrative error, the wrong version of this press release was initially published.

ILMN ILLUMINA INC. (Health Care)

ILLUMINA reduces its risk exposure and slightly improves to Neutral

The independent financial analyst theScreener just allocated a lower risk rating to ILLUMINA (US), active in the Biotechnology industry. As regards its fundamental valuation, the title still shows 2 out of 4 possible stars. Its market behaviour, however, has slightly improved and can be qualified as moderately risky. theScreener considers that these elements merit an overall rating upgrade to Neutral. As of the analysis date July 20, 2021, the closing price was USD 487.25 and its expected value was estimated at USD 450.67.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch